CD274 and neoplasm: ICB therapy could inhibit the immune checkpoint pathways such as programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) signaling, thus alleviating T cell exhaustion and enhancing CTLs-mediated tumor killing (28).